PDCD1 and non-small cell lung carcinoma: However, it is consistent with a study in which patients with NSCLC showed increased expression of a different checkpoint, killer cell Ig-like receptor, following nivolumab treatment, suggesting compensatory expression of immune checkpoints following PD-1 blockade [18].